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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. This paper provides recommendations on the management of thyroid cancer in adults and is
based on the 2014 British Thyroid Association guidelines.
Recommendations
• Ultrasound scanning (USS) of the nodule or goitre is a crucial investigation in guiding the need for fine needle
aspiration cytology (FNAC). (R)
• FNAC should be considered for all nodules with suspicious ultrasound features (U3–U5). If a nodule is smaller
than 10 mm in diameter, USS guided FNAC is not recommended unless clinically suspicious lymph nodes on
USS are also present. (R)
• Cytological analysis and categorisation should be reported according to the current British Thyroid Association
Guidance. (R)
• Ultrasound scanning assessment of cervical nodes should be done in FNAC-proven cancer. (R)
• Magnetic resonance imaging (MRI) or computed tomography (CT) should be done in suspected cases of
retrosternal extension, fixed tumours (local invasion with or without vocal cord paralysis) or when
haemoptysis is reported. When CT with contrast is used pre-operatively, there should be a two-month delay
between the use of iodinated contrast media and subsequent radioactive iodine (I131) therapy. (R)
• Fluoro-deoxy-glucose positron emission tomography imaging is not recommended for routine evaluation. (G)
• In patients with thyroid cancer, assessment of extrathyroidal extension and lymph node disease in the central
and lateral neck compartments should be undertaken pre-operatively by USS and cross-sectional imaging (CT
or MRI) if indicated. (R)
• For patients with Thy 3f or Thy 4 FNAC a diagnostic hemithyroidectomy is recommended. (R)
• Total thyroidectomy is recommended for patients with tumours greater than 4 cm in diameter or tumours of any
size in association with any of the following characteristics: multifocal disease, bilateral disease, extrathyroidal
spread (pT3 and pT4a), familial disease and those with clinically or radiologically involved nodes and/or
distant metastases. (R)
• Subtotal thyroidectomy should not be used in the management of thyroid cancer. (G)
• Central compartment neck dissection is not routinely recommended for patients with papillary thyroid cancer
without clinical or radiological evidence of lymph node involvement, provided they meet all of the following
criteria: classical type papillary thyroid cancer, patient less than 45 years old, unifocal tumour, less than 4 cm,
no extrathyroidal extension on ultrasound. (R)
• Patients with metastases in the lateral compartment should undergo therapeutic lateral and central compartment
neck dissection. (R)
• Patients with follicular cancer with greater than 4 cm tumours should be treated with total thyroidectomy. (R)
• I131 ablation should be carried out only in centres with appropriate facilities. (R)
• Serum thyroglobulin (Tg) should be checked in all post-operative patients with differentiated thyroid cancer
(DTC), but not sooner than six weeks after surgery. (R)
• Patients who have undergone total or near total thyroidectomy should be started on levothyroxine 2 μg per kg or
liothyronine 20 mcg tds after surgery. (R)
• The majority of patients with a tumour more than 1 cm in diameter, who have undergone total or near-total
thyroidectomy, should have I131 ablation. (R)
• A post-ablation scan should be performed 3–10 days after I131 ablation. (R)
• Post-therapy dynamic risk stratification at 9–12 months is used to guide further management. (G)
• Potentially resectable recurrent or persistent disease should be managed with surgery whenever possible. (R)
• Distant metastases and sites not amenable to surgery which are iodine avid should be treated with I131
therapy. (R)
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• Long-term follow-up for patients with differentiated thyroid cancer (DTC) is recommended. (G)
• Follow-up should be based on clinical examination, serum Tg and thyroid-stimulating hormone
assessments. (R)
• Patients with suspected medullary thyroid cancer (MTC) should be investigated with calcitonin and carcino-
embryonic antigen levels (CEA), 24 hour catecholamine and nor metanephrine urine estimation (or plasma
free nor metanephrine estimation), serum calcium and parathyroid hormone. (R)
• Relevant imaging studies are advisable to guide the extent of surgery. (R)
• RET (Proto-oncogene tyrosine-protein kinase receptor) proto-oncogene analysis should be performed after
surgery. (R)
• All patients with known or suspected MTC should have serum calcitonin and biochemical screening for
phaeochromocytoma pre-operatively. (R)
• All patients with proven MTC greater than 5 mm should undergo total thyroidectomy and central compartment
neck dissection. (R)
• Patients with MTC with lateral nodal involvement should undergo selective neck dissection (IIa–Vb). (R)
• PatientswithMTCwith central nodemetastases should undergo ipsilateral prophylactic lateral node dissection. (R)
• Prophylactic thyroidectomy should be offered to RET-positive family members. (R)
• All patients with proven MTC should have genetic screening. (R)
• Radiotherapy may be useful in controlling local symptoms in patients with inoperable disease. (R)
• Chemotherapy with tyrosine kinase inhibitors may help in controlling local symptoms. (R)
• For individuals with anaplastic thyroid carcinoma, initial assessment should focus on identifying the small
proportion of patients with localised disease and good performance status, which may benefit from surgical
resection and other adjuvant therapies. (G)
• The surgical intent should be gross tumour resection and not merely an attempt at debulking. (G)
Differentiated thyroid cancer
Introduction
Thyroid nodules are common, the incidence of palp-
able nodules in women and men being approximately
5 and 1 per cent, respectively. Use of ultrasound scan-
ning (USS) substantially increases their detection in the
general population to approximately 50–70 per cent.
Thyroid cancer remains rare, with an incidence in the
UK of approximately 5 per 100 000 women and 2
per 100 000 men. Thyroid cancer is the most
common endocrine malignancy, but accounts for only
1 per cent of all malignancies. Evidence suggests an
increasing incidence; however, the survival rates
remain static.
Long-term prognosis for differentiated thyroid
cancer (DTC) is excellent, with survival rates for
adults being 92–98 per cent at 10-year follow-up.
However, 5–20 per cent of patients develop local or
regional recurrence requiring further treatment and
10–15 per cent go on to develop distant metastases.
Factors influencing prognosis include gender, age at
presentation, histology and tumour stage. Accurate
diagnosis, treatment and long-term follow-up are
essential to achieve and maintain excellent survival
rates.
There have been several sets of detailed guidelines
published on the diagnosis and management of
thyroid cancer. Two key ones are the Guidelines for
the Management of Thyroid Cancer (2014) by the
British Thyroid Association and Royal College of
Physicians,1 and the Revised American Thyroid
Association Guidelines (2016).2 These documents are
extensive and cover every aspect of care in great
detail. Given differences in presentation, pathophysi-
ology and outcomes, separate guidelines exist for chil-
dren with DTC,3 and consensus statements on the
various surgical interventions.4 Patients may initially
be seen by a surgeon, endocrinologist, clinical oncolo-
gist or nuclear medicine physician, who must be a core
member of the thyroid cancer multidisciplinary team
(MDT). The goals of treatment for DTC are set out in
Box I.
BOX I
GOALS OF TREATMENT FOR DTC
• Remove the primary tumour and involved lymph
nodes
• Minimise treatment related morbidity
• Allow accurate staging of the disease
• Facilitate post-operative treatment with
radioactive iodine in appropriate patients
• Enable long-term surveillance for disease
recurrence
• Minimise the risk of disease recurrence and
distant metastases
Clinical presentation
In all cases, a detailed history is required. Clinical fea-
tures associated with an increased risk of malignancy in
individuals with a thyroid nodule include:
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• age younger than 20 or older than 60 years
• firmness of the nodule on palpation
• rapid growth
• fixation to adjacent structures
• vocal cord paralysis
• associated lymphadenopathy
• history of neck irradiation
• family history of thyroid cancer
• history of Hashimoto’s thyroiditis (risk factor for
thyroid lymphoma).
Symptoms warranting immediate referral. Patients pre-
senting with airway compromise, including stridor,
associated with a thyroid nodule or goitre should be
referred for an immediate opinion.
Symptoms warranting urgent general practitioner (GP)
referral (two-week wait rule). Patients presenting with
hoarseness of voice or a change in their voice asso-
ciated with a thyroid nodule or goitre, children with a
thyroid nodule, individuals with cervical lymphaden-
opathy associated with a thyroid nodule or a painless
thyroid mass, which is rapidly enlarging over a
period of weeks should be referred for an urgent
opinion.
Investigation
Recommended clinical investigations. These include:
• Clinical evaluation of thyroid, cervical and supra-
clavicular nodes
• Thyroid-stimulating hormone (TSH)
• Ultrasound of the nodule (Table I)
• Fine needle aspiration cytology (FNAC) if ultra-
sound features are suspicious of malignancy
• Documented cytological score (Table II). A core
biopsy (with or without USS guidance) is war-
ranted if a diagnosis of lymphoma is suspected
• Calcitonin only in suspected cases of medullary
thyroid cancer (MTC) (routine use not recommended)
• Pre-operative vocal cord check
• Note that a serum thyroglobulin (Tg) is not
recommended.
Ultrasound of thyroid nodules. Ultrasound is very useful
in the investigation of thyroid nodules and should be
used to guide the need for further investigation includ-
ing FNAC. Ultrasound-guided FNAC increases the
yield of diagnostic cytology significantly. Current
guidelines recommend that ultrasonographers use the
U grade (Table I) to classify nodules according to ultra-
sound appearances.5
Ultrasound evaluation of cervical lymphadenopathy.
Pathological studies suggest that microscopic lymph
node metastases are very common in papillary
thyroid cancer (PTC). However, macroscopic disease
is less common (20–50 per cent). Pre-operative
ultrasonography is effective in identifying suspicious
nodes in approximately 20–30 per cent of patients
with PTC and may alter the surgical approach. FNAC
of suspicious nodes is recommended. Tg estimation
of cystic fluid may be of use in the absence of sufficient
diagnostic material.
Recommendations
• Ultrasound scanning of the nodule or goitre is
a crucial investigation in guiding the need for
FNAC (R)
• FNAC should be considered for all nodules
with suspicious ultrasound features (U3–U5).
If a nodule is smaller than 10 mm in diameter,
USS-guided FNAC is not recommended
unless clinically suspicious lymph nodes on
USS are also present (R)
• Cytological analysis and categorisation
should be reported according to the current
British Thyroid Association Guidance (R)
• Ultrasound scanning assessment of cervical
nodes should be done in FNAC-proven
cancer (R)
• Magnetic resonance imaging (MRI) or
computed tomography (CT) should be done
in suspected cases of retrosternal extension,
fixed tumours (local invasion with or without
vocal cord paralysis) or when haemoptysis is
reported. When CT with contrast is used pre-
operatively, there should be a two-month
delay between the use of iodinated contrast
media and subsequent radioactive iodine
therapy (R)
• Fluoro-deoxy-glucose-positron emission
tomography imaging is not recommended for
routine evaluation (G)
Staging
The tumour, nodes and metastases (TNM) staging
system (Table III) is used to stage thyroid cancers
and this should be used in all cases. Post-operatively,
an ‘R’ classification can be given which indicates the
amount of residual disease present. The TNM classifi-
cation can then be used in combination with patient
characteristics to define likely prognosis (Table IV).
Surgery
Surgeons performing operations for confirmed or sus-
pected thyroid cancer should be core members of the
thyroid cancer MDT and should perform a minimum
of 20 thyroidectomies per year. Complex surgery and
lymph node surgery should be undertaken by nomi-
nated surgeons in the cancer centre with specific train-
ing in, and experience of, thyroid oncology. All
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patients with suspected or confirmed thyroid cancer
should have pre-operative imaging with ultrasound.
Cross-sectional imaging with CT or MRI may also be
indicated.
In the context of thyroid cancer, surgery may be
diagnostic (e.g. hemithyroidectomy following Thy 3
or Thy 4 cytology) or therapeutic.
Thyroid surgery for papillary thyroid cancer (PTC). A
strategy for the surgical treatment of PTC is detailed
in Table V. All cases should be discussed pre-opera-
tively at the thyroid cancer MDT.
Initial surgery for follicular thyroid cancer. The majority
of patients undergoing surgery for follicular thyroid
cancer will be undiagnosed at the time of the initial
surgery (Thy 3). Frozen section histology cannot cur-
rently reliably differentiate benign follicular lesions
from follicular thyroid cancer, and therefore this strat-
egy is not recommended. An operative strategy for
surgical treatment of follicular cancer is outlined in
Table VI.
Low-risk patients with a diagnosis of minimally
invasive tumour less than 4 cm following hemithyroi-
dectomy do not require further treatment. Hurthle cell
cancers (follicular oncocytic) tend to be more aggres-
sive and should be treated by total (completion) thyroi-
dectomy (see Table VI).
Management of lymph nodes in differentiated thyroid
cancer (DTC). Prophylactic level VI lymph node dis-
section is associated with a higher incidence of recur-
rent laryngeal nerve damage and long-term
permanent hypoparathyroidism.6 It is therefore not rou-
tinely recommended, but in individuals with high-risk
tumours, this should be discussed in the spirit of perso-
nalised decision making. Prophylactic level VI nodal
dissection is not recommended in low risk, small pap-
illary and most follicular cancers.
Prophylactic level VI nodal dissection is recom-
mended in patients with known involved lateral
TABLE I
U GRADING OF THYROID NODULES
U1 normal U2 benign U3 indeterminate/
equivocal
U4 suspicious U5 malignant
Normal thyroid
tissue
Halo
Iso-echoic or mildly hyper-echoic
Cystic change± ring down sign
Micro-cystic/spongiform
Peripheral egg shell calcification
Peripheral vascularity
Homogeneous
Hyper-echoic
Solid, halo
(follicular lesion)
Equivocal echogenic
foci
Cystic change
mixed/central
vascularity
Solid
Hypo-echoic or
very hypo-
echoic
Disrupted
peripheral
calcification
Lobulated
outline
Solid
Hypo-echoic
Lobulated or irregular
outline
Micro-calcification
Globular calcification
Intra-nodular
vascularity
Shape (taller >wide)
Characteristic
associated
lymphadenopathy
No follow-up
required
No follow-up required – routine FNAC
not recommended, unless high level
of clinical suspicion of thyroid
cancer
FNAC FNAC FNAC
FNAC = fine needle aspiration cytology
TABLE II
THYROID FNAC DIAGNOSTIC CATEGORIES
Thy 1 Thy 2 Thy 3 Thy 4 Thy 5
Thy 3F Thy 3A
Non-
diagnostic
Non-neoplastic,
e.g. colloid
nodule or
thyroiditis
Follicular lesion Atypia present Suspicious of thyroid
cancer
Diagnostic of thyroid
cancer
Repeat
FNAC
No follow-up if
no suspicious
US features
and no
clinical
suspicion of
thyroid cancer
Diagnostic
hemithyroidectomy∗
Consider total
thyroidectomy in
lesions >4 cm
where incidence of
malignancy is higher
Repeat ultrasound and
FNAC
If second Thy 3A
cytology obtained,
discuss at MDT and
consider diagnostic
hemithyroidectomy∗
Discuss at MDT
Diagnostic
hemithyroidectomy∗
Discuss at MDT
Appropriate further
investigations for
staging where indicated
Total thyroidectomy±
central node clearance
in appropriate high risk
patients
∗Hemithyroidectomy consists of removal of a thyroid lobe and the isthmus
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nodes. Therapeutic level VI nodal dissection is recom-
mended when the presence of lymph node metastasis is
confirmed.
Clinically involved lateral cervical lymph nodes
should be managed by selective neck dissection
(levels II–V). Involvement of level I or VII node is
rare in DTC and should only be dissected if involved.
Prophylactic lateral neck compartment dissection for
node negative patients is not recommended.
Completion thyroidectomy. Completion thyroidectomy
is not needed in low-risk, unifocal, intrathyroidal
tumours less than 4 cm in diameter, with clinically
negative lymph nodes.
Locally advanced disease. Where possible, locally
advanced disease should be resected. Preservation of
recurrent laryngeal nerves should be attempted in
almost all cases. Extensive resection of trachea,
larynx and oesophagus should be considered if poten-
tially curative. Where disease is unresectable, radio-
therapy and radioiodine should be considered.
Microcarcinomas. Microcarcinomas are differentiated
thyroid carcinomas less than 10 mm in maximum
dimension and are predominantly papillary carcin-
omas. The management of papillary microcarcinomas
is outlined in Figure 1.
Recommendations
• In patients with thyroid cancer, assessment of
extrathyroidal extension and lymph node
disease in the central and lateral neck
compartments should be undertaken pre-
operatively by USS and cross-sectional
imaging (CT or MRI) if indicated (R)
• For patients with Thy 3f or Thy 4 FNAC a
diagnostic hemithyroidectomy is
recommended (R)
• Total thyroidectomy is recommended for
patients with tumours greater than 4 cm in
diameter, or tumours of any size in
association with any of the following
characteristics: multifocal disease, bilateral
disease, extrathyroidal spread (pT3 and
pT4a), familial disease, and those with
clinically or radiologically involved nodes
and/or distant metastases (R)
TABLE III
TUMOUR, NODES AND METASTASES 7TH EDITION STAGING SYSTEM FOR DIFFERENTIATED THYROID CANCER
T stage – primary tumour TX primary tumour cannot be assessed
T0 no evidence of primary tumour
T1 tumour ≤2 cm in greatest dimension limited to the thyroid
T1a tumour ≤1 cm, limited to the thyroid
T1b tumour >1 cm but ≤2 cm in greatest dimension, limited to the thyroid
T2 tumour >2 cm but ≤4 cm in greatest dimension, limited to the thyroid
T3 tumour>4 cm in greatest dimension limited to the thyroid or any tumour with minimal
extrathyroidal extension (e.g. extension to sternothyroid muscle or peri-thyroid soft
tissues)
T4 tumour of any size extending beyond the thyroid capsule
T4a tumour invades subcutaneous soft tissues, larynx, trachea, oesophagus or recurrent
laryngeal nerve
T4b tumour invades pre-vertebral fascia or encases carotid artery or mediastinal vessel
N stage – regional lymph nodes (cervical or
upper mediastinal)
NX regional lymph nodes cannot be assessed
N0 no regional lymph node metastasis
N1 regional lymph node metastasis
N1a metastases to level VI (pretracheal, paratracheal and prelaryngeal/Delphian lymph
nodes)
N1b metastases to unilateral, bilateral, or contralateral cervical (levels I–IV or V) or
retropharyngeal or superior mediastinal lymph nodes (level VII)
M stage – distant metastases MX distant metastases cannot be assessed
M0 no distant metastasis
M1 distant metastasis
R stage – residual disease RX cannot assess presence of residual primary tumour
R0 no residual primary tumour
R1 microscopic residual primary tumour
R2 macroscopic residual primary tumour
MDT=multidisciplinary team
TABLE IV
GROUP STAGING AND SURVIVAL FOR
DIFFERENTIATED THYROID CANCER
Stage Age <45
years
Age >45 years 10-year
survival (%)
I Any T, any
N, M0
T1, N0, M0 98.5
II Any T, any
N, M1
T2, N0, M0 98.8
III T3, N0, M0 or T1–3,
N1a, M0
99.0
∗IVA T4a, any N, M0 or
T1–3, N1b, M0
75.9
IVB T4b, any N, M0 62.5
IVC Any T, any N, M1 63.0
∗Undifferentiated or anaplastic carcinomas are all stage IV
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• Subtotal thyroidectomy should not be used in
the management of thyroid cancer (G)
• Central compartment neck dissection is not
recommended for patients without clinical or
radiological evidence of lymph node
involvement, provided they meet all of the
following criteria: classical type PTC, below
45 years, unifocal tumour, less than 4 cm, no
extrathyroidal extension on US (R)
• Patients with metastases in the lateral
compartment should undergo therapeutic
lateral and central compartment neck
dissection (R)
• Patients with follicular tumours greater
than 4 cm should be treated with total
thyroidectomy (R)
Post-operative management
After total or near total thyroidectomy patients should
be commenced on suppressive doses of levothyroxine
(2 μg/kg) or liothyronine 20 mcg tds in accordance
with local protocols.
Calcium levels should be routinely checked within
24 hours and hypocalcaemia treated appropriately.
Thyroglobulin levels should be checked no earlier
than six weeks after surgery.
All patients with thyroid cancer should be clinically
staged using the TNM classification and also scored
using one of the clinicopathological scoring systems
to enable planned follow-up, identification of high
risk patients and those who would benefit from
radio-iodine therapy. In addition, all patients should
have access to a thyroid cancer clinical nurse specialist
and be given written information.
Persistent voice dysfunction should be investigated
and referral to a specialised practitioner for assessment
and speech therapy sought.
Patients with long-term hypocalcaemia (hypopara-
thyroidism) should have their calcium levels regularly
monitored either in association with an endocrinologist
or with their GP.
Following surgery, initial post-operative risk stratifi-
cation for risk of recurrence can occur.
Low-risk patients have the following
characteristics:
• No local or distant metastases
• All macroscopic tumours have been resected, i.e.
R0 or R1 resection
• No tumour invasion of locoregional tissues or
structures
• The tumour does not have aggressive histology
(tall cell or columnar cell PTC, diffuse sclerosing
PTC, poorly differentiated elements) or
angioinvasion.
TABLE V
INITIAL SURGERY FOR PAPILLARY THYROID CARCINOMA
Tumour <4 cm Tumours >/=4 cm T3 and T4 tumours
+N1 level VI nodes,
M1
Recommendation With no other clinical features
such as age >45 years,
extrathyroidal spread, nodal
involvement, angioinvasion,
multifocality, distant
metastases
Papillary cancer diagnosed
following hemithyroidectomy,
multifocal disease, thyroid
radiation in childhood, familial
disease (first degree relative)
Treat all above tumours
as high risk
Hemithyroidectomy Yes No No
Total thyroidectomy Discuss at MDT Completion total thyroidectomy Yes
Prophylactic level VI nodal dissection No Personalised decision making Yes
Therapeutic level VI nodal dissection
(clinically involved)
Yes Yes Yes
TABLE VI
INITIAL SURGERY FOR FOLLICULAR THYROID CANCER
Clinical details
Recommendation Low-risk patient (with all of following)
<45 years
>1–≤4 cm
Minimally invasive
No angioinvasion
No extracapsular invasion
No extrathyroidal spread
High-risk patient (one or more of the following)
>45 years
Tumour >4 cm
Extra-capsular invasion
Extrathyroidal disease
Widely invasive
Angioinvasion
Hurthle cell tumours
Hemithyroidectomy Yes No
Total thyroidectomy No Yes
Level VI nodal dissection No Only where clinically involved nodes present
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Intermediate-risk patients have any of the following
characteristics:
• Microscopic invasion of tumour into the peri-thyr-
oidal soft tissues (T3) at initial surgery
• Cervical lymph node metastases (N1a or N1b)
• Tumour with aggressive histology (tall cell or col-
umnar cell PTC, diffuse sclerosing PTC, poorly
differentiated elements) or angioinvasion.
High-risk patients have any of the following
characteristics:
• Extrathyroidal invasion
• Incomplete macroscopic tumour resection (R2)
• Distant metastases. (M1)
Radioiodine (I131) ablation and external beam
radiotherapy (EBR) in DTC
The current recommendations with regards to I131 abla-
tion following total thyroidectomy are outlined in
Table VII.
Patients should be prepared for I131 by having a low-
iodine diet for one to two weeks prior to treatment.
Recombinant TSH (rhTSH) therapy prior to I131 is
preferable to thyroid hormone withdrawal, and is pre-
ferred by patients, providing they meet the following
criteria: pT1 to T3, pN0 or NX or N1, and M0 and
R0 (no microscopic residual disease). Pregnancy
should be excluded prior to giving I131. A post-ablation
FIG. 1
Flow diagram outlining management of papillary microcarcinomas. Multiple risk factors may tip the balance in favour of total thyroidectomy.
TABLE VII
INDICATIONS FOR I131 ABLATION FOLLOWING TOTAL
THYROIDECTOMY FOR DIFFERENTIATED THYROID
CANCER
Recommendation Clinical details
Definite I131 ablation Tumour >4 cm
Any tumour size with gross
extrathyroidal extension
Distant metastases present
Probable I131 ablation
Consider on individual
case merit (MDT)
Risk factors indicating higher
risk of recurrence where I131
should be considered include:
Large tumour size
Extrathyroidal extension
Unfavourable cell type (tall cell,
columnar or diffuse sclerosing
papillary cancer, poorly
differentiated elements)
Widely invasive histology
Multiple lymph node
involvement, large size of
involved lymph nodes, high
ratio of positive-to-negative
nodes, extracapsular nodal
involvement
No I131 ablation (all
criteria must be met)
Tumour <1 cm unifocal or
multifocal
Histology classical papillary or
follicular variant of papillary
carcinoma, or follicular
carcinoma
Minimally invasive without
angioinvasion
No invasion of thyroid capsule
(extrathyroidal extension)
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scan should be performed after I131 when residual
activity levels permit satisfactory imaging. Practically,
this is generally 2–10 days following treatment.
Following I131, TSH should be suppressed to
<0.1 mIU/l pending dynamic risk stratification at
9–12 months.
Adjuvant EBR should be considered in unresectable
tumours in addition to I131 and where there is residual
disease following surgical resection even if the residual
tumour concentrates I131.
In the 9 to 12 months following surgery and I131 for
DTC with an R0 resection, patients should undergo
dynamic risk stratification (Table VIII). Patients are
then categorised as having either an excellent response,
an indeterminate response or an incomplete response.
Monitoring Tg levels. Thyroglobulin monitoring is most
effective following total or near total thyroidectomy
and I131 and is an important modality in detecting
residual or recurrent disease. Physicians should be
aware that Tg estimations vary according to the assay
method, the individual laboratory and the presence of
anti-Tg antibodies and take these considerations into
account when evaluating Tg levels in individual
patients.
The patient should have their Tg levels checked at
6–12 monthly intervals. Rising Tg levels are highly
suspicious of recurrent disease. Thyroglobulin evalu-
ation is most effective following TSH stimulation,
either by direct rhTSH stimulation or by withdrawal
of thyroid hormone replacement.
Following total or near total thyroidectomy and I131
ablation, low-risk patients with undetectable Tg levels
on TSH suppression should have a TSH-stimulated
Tg assessment along with ultrasound of cervical
nodes at 9–12 months following I131 ablation. If Tg
levels remain undetectable following TSH stimulation,
then future recurrent disease is highly unlikely and
patients may revert to yearly Tg estimation whilst
remaining on TSH suppression.
A rise in Tgmay be suggestive of recurrent or residual
disease, but is usually from a thyroid remnant. In low-
risk patients, an expectant policy can be maintained
and repeated TSH stimulated assessment performed,
with the expectation that Tg levels will fall. Rising or
persistently elevated Tg needs further evaluation.
The use of rhTSH-stimulated Tg estimation or
rhTSH I131 therapy is necessary in the following
cases: hypopituitarism, functional metastases (suppres-
sing TSH), severe angina, advanced disease (frail
patient) and history of psychiatric disturbance from
hypothyroidism.
Recommendations
• I131 ablation or therapy should be carried out
only in centres with appropriate facilities (R)
• Serum Tg should be checked in all post-
operative patients with DTC, but not earlier
than six weeks after surgery (R)
• Patients who have undergone total or near
total thyroidectomy should be started on
levothyroxine 2 μg/kg or liothyronine 20 mcg
tds after surgery (R)
• The majority of patients with a tumour more
than 1 cm in diameter, who have undergone
total or near-total thyroidectomy, should have
I131 ablation or therapy (R)
• A post-ablation scan should be performed
3–10 days after I131 ablation (R)
• Post-therapy dynamic risk stratification at
9–12 months is used to guide further
management (G)
Persistent and recurrent disease, locoregional
recurrence and distant metastases
Potentially resectable disease is best managed by
surgery (including local cervical nodes and soft tissue
disease in the neck), followed by I131. Residual
disease not amenable to resection or resistant to I131
therapy is best treated with high dose palliative EBR.
Therapeutic central compartment, with or without
lateral compartment, nodal clearance should therefore
TABLE VIII
DYNAMIC RISK STRATIFICATION FOLLOWING
TREATMENT FOR DTC AND TSH SUPPRESSION
TARGETS FOR PATIENTS TREATED WITH TOTAL
THYROIDECTOMY AND I131 ABLATION WITH
R0 RESECTION
Excellent response Indeterminate
response
Incomplete response
All the following:
Suppressed and
stimulated
Tg< 1 lg/l∗
Neck US without
evidence of
disease
Cross-sectional
and/or nuclear
medicine
imaging
negative (if
performed)
Any of the
following:
Suppressed
Tg< 1 lg/l∗
and stimulated
Tg≥ 1 and
<10 lg/l∗
Neck US with
non-specific
changes or
stable sub
centimetre
lymph nodes
Cross-sectional
and/or nuclear
medicine
imaging with
non-specific
changes,
although not
completely
normal
Any of the following:
Suppressed
Tg≥ 1 lg/l∗ or
stimulated
Tg≥ 10 lg/l∗
Rising Tg values
Persistent or newly
identified disease
on cross-sectional
and/or nuclear
medicine imaging
Low risk
Maintain TSH
0.3–2.0 mIU/l
Intermediate risk
Suppress TSH
0.1–0.5 mIU/l
for 5–10 years
then reassess
High risk
Suppress
TSH< 0.1 mIU/l
indefinitely
∗Assumes the absence of interference in the Tg assay. Tg= thyro-
globulin; TSH= thyroid stimulating hormone; US= ultrasound
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be performed for all persistent or recurrent disease con-
fined to the neck. Impalpable nodes greater than
5–8 mm seen onUSS or cross-sectional imaging follow-
ing I131 therapy should be considered for removal.
Removing nodes less than 5–8 mm has not be shown
to be of benefit.
Where technically feasible, tumours invading the
aero-digestive tract should be resected in combination
with radiotherapy. Outcome is very dependent on com-
pleteness of resection and preservation of function.
Great care should therefore be taken in the selection
and discussion of such patients at the MDT.
Distant metastases develop in 5–23 per cent of patients
withDTC. Sites not amenable to surgical resection should
be treated with I131 therapy. Long-term survival may be
expected in patients whose tumours take up I131. Distant
metastases are usually seen in the lungs and bones.
There is no maximum limit to the cumulative dose of
I131 that patients with persistent disease may receive and
pulmonary fibrosis appears to be a rare side effect.
Surgical resection of bony metastases should be consid-
ered (especially in patients below 45 years of age).
Metastases not cured by I131 should be treated with
EBR.Othermodalities such as intra-arterial embolisation,
pamidronate infusion, radiofrequency ablation or verteb-
roplasty may be considered in cases of painful lesions.
Recommendations
• Potentially resectable recurrent or persistent
disease should be managed with surgery
whenever possible (R)
• Distant metastases and sites not amenable to
surgery, which are iodine avid should be
treated with I131 therapy (R)
Long-term follow-up
Lifelong follow-up of DTC is recommended to monitor
for late recurrence (often treatable and curable), effects
of long-term TSH suppression (atrial fibrillation and
osteoporosis) and late side effects of I131. Clinical
examination and history, Tg determination, TSH sup-
pression and where necessary calcium monitoring
should all be performed. Ultrasound scanning as per
established protocols may also be undertaken.
Recommendations
• Long-term follow-up for patients with DTC is
recommended (G)
• Follow-up should be based on clinical
examination, serum Tg and TSH
assessments (R)
Medullary thyroid cancer
Introduction
Medullary thyroid cancer (MTC) is a rare cancer
(approximately 1–3 per cent of all thyroid cancer
cases). All cases should be referred for surgical treat-
ment to the designated cancer centre of the Thyroid
Cancer Network. Twenty-five per cent of MTC cases
are familial (MEN2A, MEN2B and familial non-
MEN MTC). Genetic screening (RET mutation
testing) of all patients is mandatory and the assessment,
investigation and treatment of family members at
potential risk requires a multidisciplinary approach
within the cancer centre.7
Clinical presentation
Patients usually present clinically with a thyroid nodule
or neck mass with or without cervical lymphadenop-
athy (in the same fashion as with DTC). History
however, may reveal other symptoms such as flushing,
loose stools or diarrhoea (which suggest MTC) and is
vitally important in determining a potential familial
element. FNAC may be diagnostic (when combined
with calcitonin staining in suspicious cases), but
often is reported as Thy 3.
Investigation
When MTC is suspected (or proven) patients must
undergo the following investigations prior to surgery8:
• Calcitonin and CEA levels
• Twenty-four-hours urine estimation of cate-
cholamines and nor metanephrines (or plasma
nor metanephrines) to identify or exclude phaeo-
chromocytoma
• Serum calcium and parathyroid hormone (PTH) to
identify or exclude hyperparathyroidism
• CT, MRI or USS of the neck are indicated as they
may help guide the extent of surgical resection at
initial surgery
• RET proto-oncogene mutational analysis should
be performed after surgery once diagnosis is
established, even in the absence of a familial
history.
Staging
TNM staging for MTC follows the same criteria as for
DTC (Table IX).
TABLE IX
GROUP STAGING FOR MEDULLARY THYROID CANCER
Stage I T1, N0, M0
Stage II T2, T3, T4, N0, M0
Stage III Any T, N1, M0
Stage IV Any T, any N, M1
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Recommendations
• Patients with suspected MTC should be
investigated with calcitonin and CEA levels,
24 hours catecholamine and nor
metanephrine urine estimation (or plasma
free nor metanephrine estimation), serum
calcium and PTH (R)
• Relevant imaging studies are advisable to
guide the extent of surgery (R)
• RET proto-oncogene analysis should be
performed after surgery (R)
Management-surgery for MTC
All patients with MTC should undergo8:
• Total thyroidectomy and central compartment
node clearance (level VI). This should be per-
formed even in the presence of disseminated
metastases to control local disease.
• In the presence of central compartment lymph
node metastases, ipsilateral prophylactic neck dis-
section is recommended as up to 70 per cent of
patients will have lateral nodal metastases.
• Patients with clinically involved lateral compart-
ment nodes should have a therapeutic lateral
neck dissection to eradicate local disease.
• All T2–T4 tumours should also undergo prophy-
lactic bilateral selective neck dissection IIa–Vb.
• Intra-thoracic disease below the level of the bra-
chiocephalic vein should be resected via sternot-
omy where feasible.
• Prophylactic thyroidectomy should be offered to
RET-positive family members. Timing and
extent of surgery are dependent on genotype
(codon mutation), the calcitonin level and age at
detection of RET positivity.
Persistent or recurrent MTC
Calcitonin levels are most informative six months after
initial surgery. It is important to distinguish persistent
locoregional disease (following either inadequate
initial surgery or local lymph node metastases) from
distant disease.
Early local recurrence following adequate local
surgery (total thyroidectomy and level VI nodes) is
unusual. The likely source of raised calcitonin in this
circumstance is the lateral compartment cervical
nodes, i.e. persistent disease. When indicated, re-
operation including further central compartment
surgery and lateral neck node dissection should be per-
formed. The primary aim should always be to control
local disease.
CT, MRI, USS, selective arteriography, I131-metaio-
dobenzylguanidine, 18Fluoro-deoxy-glucose positron
emission tomography, In111-octreotide and direct laparo-
scopic visualisation of the liver may all be useful in
identifying the source of a raised calcitonin, but their
use in patients with calcitonin levels <400–500 pg/
ml is unlikely to identify metastases. When indicated,
isolated metastases should be considered for surgical
resection.
Recommendations
• All patients with known or suspected MTC
should have serum calcitonin and biochemical
screening for phaeochromocytoma pre-
operatively (R)
• All patients with proven MTC >5 mm should
undergo total thyroidectomy and central
compartment neck dissection (R)
• Patients with lateral nodal involvement should
undergo selective neck dissection (IIa–Vb)
(R)
• Patients with central node metastases should
undergo ipsilateral prophylactic lateral node
dissection (R)
• Prophylactic thyroidectomy should be offered
to RET-positive family members (R)
• All patients with proven MTC should have
genetic screening (R)
Radiotherapy and chemotherapy
Radiotherapy is of use in controlling local symptoms in
patients with inoperable disease and improving the
relapse-free rate following central or lateral compart-
ment surgery where residual disease is present macro-
scopically or microscopically.
Tyrosine kinase inhibitors can be effective in con-
trolling symptoms in patients with metastatic disease.
Somatostatin analogues may be effective in alleviat-
ing the unpleasant gastrointestinal symptoms that
patients with advanced cases of MTC experience.
Recommendations
• Radiotherapy may be useful in controlling
local symptoms in patients with inoperable
disease (R)
• Chemotherapy with tyrosine kinase inhibitors
may help in controlling local symptoms (R)
Follow-up
Lifelong follow-up is recommended for all patients
with MTC. Screening should include calcitonin and
CEA. Thyroid-stimulating hormone suppression is
not necessary. Rising calcitonin levels should trigger
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investigations to identify potentially treatable metastat-
ic disease.
Anaplastic thyroid cancer
The prognosis of patients with anaplastic thyroid
cancer (ATC) is poor. Many patients present with a
history of a rapidly enlarging thyroid mass in a long-
standing goitre. Diagnosis can be established by fine
needle aspiration or core biopsy. Core biopsy will
help differentiate ATC from thyroid lymphoma which
can present in a similar manner.
Total thyroidectomy may be curative for very small
cancers. In more advanced disease surgery may be of
benefit if R0/R1 resection is achievable.9 External
beam radiotherapy and chemotherapy may be used as
adjuvant treatments in patients with R0/R1 resection
and no evidence of distant disease. ‘Debulking’
surgery should be avoided when complete resection
cannot be achieved. Palliative chemoradiation may be
of some value in selected cases. Palliative care has a
principal role in management of these patients.
Recommendations
• Initial assessment should focus on identifying
the small proportion of patients with localised
disease and good performance status, who
may benefit from surgical resection and other
adjuvant therapies (G)
• The surgical intent should be gross tumour
resection and not merely an attempt at
debulking (G)
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